COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3018 participants.
Also called NCT04642430
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,018 participants
- Registry
-
NCT04642430
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT04642430. Randomized; single masking; primary purpose treatment. Start 2021-07-06 (actual); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
- Acronym
- COBRRA-AF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Rivaroxaban
- Lead sponsor
- Ottawa Hospital Research Institute
- Collaborator
- Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
- Collaborator
- Canadian Institutes of Health Research (CIHR)
Record details
- Record id
cardio:ct-nct04642430- Content hash
c3ca09cce8bb0ef3e24730d36b1ab36aa6a283a83ece604560cb72e2c759beca